title: Pathology, therapy and prognosis of papillary renal carcinoma.
abstract: Papillary renal cell carcinoma (pRCC) accounts for approximately 10% of renal parenchymal tumors. There are two pRCC subtypes reported in several studies, but at present, there is limited molecular evidence to validate this pRCC subtyping in the daily routine. The utility of subtyping pRCC is based on reports describing that pRCC subtype is an independent predictor of outcome, with type 1 tumors showing significantly better survival than type 2 tumors. In this article, we summarize the relevant knowledge on pRCC regarding tumor features: clinical presentation, histopathology, electron microscopy, immunohistochemistry, cytogenetics, genetic/molecular and prognosis. We present an overview of the currently available pRCC treatment options and some of the new promising agents.
authors.affiliation: Faculty of Medicine, University of Porto, 4099-002 Porto, Portugal.
authors.forename: Diana Silva
authors.initials: DS
authors.lastname: Fernandes
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Lopes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D002869:Chromosome Aberrations; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents
keywords: chromosomal; epidemiology; genetic; immunohistochemical; morphology; papillary renal cell carcinoma; prognosis; treatment